Tuesday, November 14th 2017
09:05 – 10:00 h 1st SESSION: EPIGENOMIC AND CANCER
09:05 – 09:20 h Small molecules targeting epigenetic modulators for cancer treatment
Dr. Xabier Aguirre, Centro de Investigación Médica Aplicada-CIMA, Universidad de Navarra, Pamplona
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/1.-Xabier-Aguirre.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
09:20 – 09:35 h Transfer RNA methylation in cancer
Dra. Sandra Blanco, CIC bioGUNE, Derio
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/2.-Sandra-Blanco.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
09:35 – 09:40 h Oral communication Inhibition of a G9A-EZH2 network triggers an immune-mediated bladder cancer regression
Dra. Cristina Segovia, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas-CIEMAT, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/3.-Cristina-Segovia.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
09:40 – 09:45 h Oral communication Correlation between tumor history and microenvironment using multiregion single-molecule epigenomic data from colorectal cancer patients
Dr. José Luis Soto, Universidad de Vigo
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/4.-Jos-Luis-Soto.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
10:00 – 10:35 h EMERGING TOPICS IN CANCER: TUMOR EVOLUTION
10:05 – 10:30 h Speaker:
Dr. David Posada, Universidad de Vigo
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/5.-David-Posadav2.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
11:10 – 12:20 h 2nd SESSION: IMMUNOLOGY AND CANCER
11:25 – 11:40 h Immunotherapy resistance modes: primary, adaptative and acquired
Dr. Rafael Rosell, Hospital Universitari Germans Trias i Pujol-ICO, Badalona
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/7.-Rafael-Rosell.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
11:40 – 11:55 h Microbiome and the modulation of the immune system
Dr. Andrés Moya, Universidad de Valencia
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/8.-Andres-Moya.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
11:55 – 12:00 h Oral communication The zebrafish: a new model to understand the crosstalk between inflammation and cancer
Dr. Victoriano Mulero, Universidad de Murcia
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/9.Victoriano-Mulero.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
12:00 – 12:05 h Oral communication Novel molecular mechanisms of immunoresistance and cancer stem cell activity
Dr. Ander Sáenz, Instituto de Investigación Sanitaria Biodonostia, Donostia
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/10.-Ander-Saenz.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
12:40 – 13:25 h RECENT ADVANCES IN BREAST CANCER
12:40 – 12:55 h Emerging therapeutic strategies
Dra. Eva Ciruelos, Hospital Universitario 12 de Octubre, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/11.-Eva-Ciruelos.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
12:55 – 13:10 h Research advances towards disease eradication
Dr. Alberto Ocaña,Complejo Hospitalario Universitario de Albacete
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/12.-Alberto-Ocaña.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
14:25 – 15:10 h RECENT ADVANCES IN LUNG CANCER
14:25 – 14:40 h Emerging therapeutic strategies
Dra. Pilar Garrido,Hospital Universitario Ramón y Cajal, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/13.-Pilar-Garrido-min.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
14:40 – 14:55 h Research advances towards disease eradication
Dra. Montserrat Sánchez Céspedes,Institut d’Investigació Biòmedica
de Bellvitge-IDIBELL, Barcelona
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/14.-Montserrat-Sanchez-Cespedes.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
15:10 – 15:55 h THE ASEICA FORUM. CURRENT STATUS OF RESEARCH IN SPAIN
15:10 – 15:25 h Speaker:
Dr. Joaquín Arribas, CIBERONC Director
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/15.-Joaquin-Arribas.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
15:55 – 17:20 h 3rd SESSION: ASEICA – SEOM NOVEL THERAPEUTIC TARGETS AND APPROACHES FOR THE TREATMENT OF CANCER
16:10 – 16:25 h Driver genes in hematological neoplasias: role of mutations in non-coding regions
Dr. Xosé Puente, Universidad de Oviedo
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/17.-Xose-Puente.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
16:25 – 16:40 h Clinically relevant novel drivers in glioblastoma
Dr. Juan Manuel Sepúlveda, Hospital Universitario 12 de Octubre, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/18.-Juan-Manuel-Sepulveda.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
16:40 – 16:55 h Novel hallmarks of cancer
Dr. Alberto Ocaña, Complejo Hospitalario Universitario de Albacete
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/19.-Alberto-Ocaña.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
17:00 – 17:05 h Oral communication Novel therapeutic targets: aiming at VAV2 in Squamous Cell Carcinoma
Dr. Luis Francisco Lorenzo, Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/21.-Luis-Francisco-Lorenzo.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
Wednesday, November 15th 2017
09:00 – 10:00 h ASEICA & CIBER CAREER PROSPECTS FOR CANCER RESEARCHERS IN TRAINING
09:00 – 09:15 h The importance of mentorship
Dra. Ana Rio-Machin, CERU representative, London, UK
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/22.-Ana-Rio-Machin.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
09:15 – 09:30 h Searching for a postdoctoral position
Dr. Amancio Carnero, Instituto de Biomedicina de Sevilla. Campus Hospital Universitario Virgen del Rocío
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/23.-Amancio-Carnero.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
09:30 – 09:45 h Paving the way to a successful career in cancer research
Dra. Angélica Figueroa, Instituto de Investigación Biomédica de A Coruña-INIBIC
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/24.-Angelica-Figueroa.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
10:00 – 11:10 h 4th SESSION: LIQUID BIOPSY. CHASING CIRCULATING TRACES OF CANCER
10:15 – 10:30 h Use of circulating exosomes as surrogate markers of tumours, the future of the liquid biopsy?
Dr. Héctor Peinado, Centro Nacional de Investigaciones Oncológicas-CNIO, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/26.-Hector-Peinado.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
10:30 – 10:45 h Alternative forms of liquid biopsy
Dr. Miguel Abal, Instituto de Investigación Sanitaria de Santiago-IDIS/SERGAS, Santiago de Compostela
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/27.-Miguel-Abal.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
10:45 – 10:50 h Oral communication Identification of potentially druggable mutations using the liquid biopsy in familial PDAC
Dra. Julie Earl, Hospital Universitario Ramón y Cajal, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/28.-Julie-Earl.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
10:50 – 10:55 h Oral communication Clinical utility of plasma-based next-generation sequencing (NGS) for advanced NSCLC patients with insufficient or unavailable tumor tissue
Dra. Eloisa Jantus, Fundación Investigación Hospital General Universitario de Valencia
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/29.-Eliosa-Jantus.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
11:55 – 13:10 h ASEICA DEBATES WITH THE EXPERT: CANCER-SPECIFIC CHALLENGES
11:55 – 12:10 h Molecular classification in colon cancer
Dr. Héctor García Palmer, Hospital Universitari Vall d’Hebron, Barcelona
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/30.-Hector-Garcia-Palmer.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
12:10 – 12:25 h Why is pancreatic cancer so difficult to treat?
Dr. Francisco X. Real, Centro Nacional de Investigaciones Oncológicas-CNIO, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/31.-Francisco-X.-Real.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
12:25 – 12:40 h Exploiting genomic instability in ovarian and prostate cancer: PARP inhibitors
Dr. Luis Manso, Hospital Universitario 12 de Octubre, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/32.-Luis-Manso.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
12:40 – 12:55 h Molecular classification in breast cancer
Dra. Laura García Estévez, Hospital Universitario HM Sanchinarro-CIOCC, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/33.-Laura-Garcia-Estevez.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
13:10 – 13:55 h RECENT ADVANCES IN PROSTATE CANCER
13:10 – 13:25 h Emerging therapeutic strategies
Dr. Daniel Castellano, Hospital Universitario 12 de Octubre, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/34.-Daniel-Castellano.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
13:25 – 13:40 h Research advances towards disease eradication
Dra. Rebeca Lozano, Centro Nacional de Investigaciones Oncológicas-CNIO, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/35.-Rebeca-Lozano.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
14:55 – 15:40 h RECENT ADVANCES IN COLON CANCER
15:10 – 15:25 h Research advances towards disease eradication
Dr. Gabriel Capellà, Institut d’Investigació Biòmedica de Bellvitge-IDIBELL, Barcelona
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/37.-Gabriel-Capella.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
15:40 – 16:30 h THE NEW FRONTIER OF CANCER
15:45 – 16:25 h Speakers:
A clinical vision:
Dr. Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/38.-Luis-PazAres.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
A biological vision:
Dr. Ángel Carracedo, Universidad de Santiago de Compostela
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/39.-Angel-Carracedo.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
16:30 – 17:45 h 5th SESSION: RESEARCH AND DIAGNOSTIC PLATFORMS
16:30 – 16:45 h Precision medicine and Big Data
Dr. Víctor Quesada, Universidad de Oviedo
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/40.-Victor-Quesada.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
16:45 – 17:00 h Delivering precision medicine in oncology today and in future
Dr. Joan Albanell, Hospital del Mar – Parc de Salut Mar, Barcelona
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/41.-Joan-Albanell.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
17:00 – 17:15 h Patient-derived xenograft applications
Dr. Alberto Villanueva, Hospital Duran i Reynals-ICO, Barcelona
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/42.-Alberto-Villanueva.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
17:15 – 17:20 h Oral communication New CRISPR/CAS9- based mouse model for the study of gliomas
Dr. Álvaro Curiel, Centro Nacional de Investigaciones Oncológicas-CNIO, Madrid
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/43.-Alvaro-Curiel.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]
17:20 – 17:25 h Oral communication Multifunctional theranostic nanoemulsions for targeted imaging and drug delivery in metastatic cancer
Dra. Sandra Díez, Fundación Ramón Domínguez, Santiago de Compostela
[su_button url=»https://www.aseica.es/wp-content/uploads/2017/11/44.-Sandra-Diez.pdf» target=»blank» style=»flat» background=»#002f5b» size=»2″]Presentación[/su_button]